A Decade of Endovascular Management in Budd–Chiari Syndrome: A Single-Centre Retrospective Review and Clinical Outcomes
This single-center retrospective study of 93 Indian adult patients demonstrates that endovascular interventions for Budd–Chiari syndrome are safe and effective, achieving 100% technical success and high long-term clinical success, patency, and survival rates over a decade.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
The liver is the body's central processing plant, filtering blood and removing toxins before that blood returns to the heart. For this system to work, blood must flow freely out of the liver and into the main vein that carries it back to the heart. When this exit route gets blocked, pressure builds up inside the liver, causing it to swell, scar, and eventually fail. This condition is known as Budd-Chiari syndrome. While rare in many parts of the world, it appears more frequently in Asia, where the blockage often takes the form of a thin, web-like membrane or a short, tight narrowing in the large vein just above the liver, rather than a total clot. Because the liver is a vital organ, finding a way to clear these blockages without performing open-heart surgery has been a major goal for doctors. The challenge lies in navigating these narrow, often twisted pathways with tiny instruments to restore flow, a task that requires immense precision and carries significant risk.
For over a decade, a team of specialists at a major medical center in India has been refining this delicate work. They looked back at the records of 93 adult patients who had undergone these minimally invasive procedures between 2013 and 2025. The goal was to see how well these techniques worked over the long term and to understand which patients benefited most. The doctors focused on a specific approach: using catheters and balloons to open up the blocked veins from the inside, a method called endovascular intervention. In some cases, they simply widened the narrowed area; in others, they placed a small mesh tube, or stent, to keep it open. When the blockage was too complex for simple widening, they created a new channel for the blood to bypass the liver entirely, a procedure known as a shunt. By reviewing the outcomes of these 93 individuals, the researchers aimed to determine if this approach was safe enough to be the standard of care and how long the results lasted.
The results of this review were striking. Every single procedure was technically successful, meaning the doctors were able to reach the blockage and open it up as intended. This is a rare feat in medicine, where complications often prevent a procedure from being completed. The patients, whose average age was just under 30, showed that the treatment worked not just immediately, but for years. Within one month of the procedure, more than 90 percent of the patients showed clear signs of improvement, such as reduced swelling in the legs or less fluid buildup in the belly. Over the course of five years, the vast majority of patients remained alive and free from the need for further major surgery. The study found that the veins stayed open in about 85 percent of patients after one year, and roughly 78 percent after five years. Even more importantly, the five-year survival rate for the entire group was nearly 96 percent.
The researchers also examined whether the type of blockage or the specific method used made a difference in the long run. They found that whether a patient had a blockage in the main vein alone, in the liver veins alone, or in both, the success rates were remarkably consistent. Similarly, there was no significant difference in survival or how long the veins stayed open between patients who had the blockage simply opened up and those who required the more complex bypass procedure. This suggests that the choice of treatment can be tailored to the specific anatomy of the patient without worrying that one method is inherently superior to the other in terms of long-term survival. The study did note that a small number of patients, about 12 percent, needed a second procedure later on to clear a re-narrowing, but these repeat interventions were also successful.
Of course, the path was not without risk. The study recorded four deaths, all occurring within the first month of the procedure. Three of these were due to the liver failing because it was already too damaged before the surgery began, and one was caused by a rare, severe bleeding complication during the procedure itself. These events serve as a sobering reminder that while the technique is highly effective, it is not without danger, particularly for patients whose livers are already in poor condition. The researchers emphasized that these outcomes were achieved in a high-volume center with highly experienced operators, suggesting that the results might be harder to replicate in hospitals with less specialized experience. They also noted that the study was retrospective, meaning they looked at past records rather than following patients in a controlled, forward-looking experiment, which can sometimes introduce biases.
Despite these limitations, the findings offer a clear picture of the current state of care for this difficult condition. The study confirms that for the majority of patients with Budd-Chiari syndrome, especially those with the specific types of blockages common in Asia, opening the veins from the inside is a safe and durable solution. It avoids the trauma of major surgery and provides a high likelihood of long-term survival. The data suggests that the key to success lies in matching the right procedure to the patient's specific anatomy and ensuring that the treatment is performed by a team with deep expertise in these complex vascular interventions. For the patients in this study, and for the many others who share their condition, these results provide a strong foundation for hope and a clear direction for future medical care.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.